Hard to work out how bigger compromises they have made on the programme’s . If the original studies were powered properly ( not overkill) I can only think that the results we have won’t be worth much in getting regulatory outcomes. Does this mean everything will need to be redone meaning huge delays and expense ?
understand it’s out of their control but very disappointing and think they should have given us visibility of the revised timeline’s and budget impact if we have delays to commercialisation.
already halved my money don’t want a CR.
I am Moving to Hold from Buy
- Forums
- ASX - By Stock
- CP1
- Ann: Quarterly Cash Flow Report & Market Update 31 March 2020
Ann: Quarterly Cash Flow Report & Market Update 31 March 2020, page-3
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CP1 (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online